Dendritic Cells Induce Specific Cytotoxic T Lymphocytes against Prostate Cancer TRAMP-C2 Cells Loaded with Freeze-thaw Antigen and PEP-3 Peptide |
Liu, Xiao-Qi
(Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University)
Jiang, Rong (Department of Stem Cell and Tissue Engineering, Chongqing Medical University) Li, Si-Qi (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University) Wang, Jing (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University) Yi, Fa-Ping (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University) |
1 | Bolhassani A, Safaiyan S, Rafati S (2011). Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer, 10, 3. |
2 | Chiang CL, Benencia F, Coukos G (2010). Whole tumor antigen vaccines. Semin Immunol, 22, 132-43. DOI |
3 | Chiang CL, Hagemann AR, Leskowitz R, et al (2011). Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One, 6, 28732. DOI |
4 | Clive KS, Tyler JA, Clifton GT, et al (2012). The GP2 peptide: A HER2/neu-based breast cancer vaccine. J Surg Oncol, 105, 452-8. DOI |
5 | Drake CG (2010). Prostate cancer as a model for tumor immunotherapy. Nat Rev Immunol, 10, 580-93. DOI ScienceOn |
6 | Furnari FB, Huang HJ, Cavenee WK (1996). Molecular biology of malignant degeneration of astrocytoma. Pediatr Neurosurg, 24, 41-9. DOI |
7 | Guo K, Liu CX (2010). Research progress on the serum markers of prostate cancer. J Practical Med, 26, 3465-6. |
8 | Gilboa E, Nair SK, Lyerly HK (1998). Immunotherapy of cancer with dendritic-cell-based vaccines. Immunother, 46, 82-7. DOI |
9 | Hong Ge, Xiaoqi Gong, Careen K (2002). Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer, 98, 357-61. DOI |
10 | Heimberger AB, Crotty LE, Archer GE, et al (2003). Epidermal growth factor receptor variant VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res, 11, 4247-54. |
11 | Inaba K, Inaba M, Romani N, et al (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colonystimulating factor. J Exp Med, 176, 1693-702. DOI |
12 | Jacques Ferlay, Hai-Rim Shin, Freddie Bray, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI |
13 | Kreiter S, Diken M, Selmi A, et al (2011). Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol, 23, 399-406. DOI |
14 | Kang TH, Mao CP, La V, Chen A, et al (2013). Innovative DNA vaccine to break immune tolerance against tumor self-antigen. Hum Gene Ther, 24, 181-8. DOI |
15 | Lee HJ, Hong CY, Kim MH, et al (2012). In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. Exp Mol Med, 44, 60-7. DOI |
16 | Lorenzi S, Mattei F, Sistigu A, et al (2011). Type I IFNs control antigen retention and survival of CD8a (+) dendritic cells after uptake of tumor apoptotic cells leading tocrosspriming. J Immunol, 186, 5142-50. DOI |
17 | Long JR, Xiong F, Dong ZQ (2010). Research progress on multiple drug resistance of prostate cancer. Guangdong Med J, 31, 2871-3. |
18 | McDonnell AM, Prosser AC, Van Bruggen I, et al (2010). CD8alpha+DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol, 40, 1617-27. DOI |
19 | Matera L (2011). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev, 36, 131-41. |
20 | Morandi F, Chiesa S, Bocca P, et al (2006). Tumor mRNAtransfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia, 10, 833-42. |
21 | Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |
22 | Park MH, Yang DH, Kim MH, et al (2011). Alpha-Type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer. Cancer Res Treat, 43, 56-66. DOI |
23 | Quintarelli C, Dotti G, Hasan ST, et al (2011). High-avidity cytotoxic-T-lymphocytes specific for a new preferentially expressed antigen of melanoma (PRAME)-derived peptide can target leukemic- and leukemic-precursor cells. Blood, 117, 3353-62. DOI |
24 | Roupret M, Zigeuner R, Palou J, et al (2011). European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol, 59, 584-94. DOI ScienceOn |
25 | Stockwin LH, McGonagle D, Martin IG, et al (2000). Dendritic cells immunological sentinels with a central role in health and disease. Immunol Cell Biol, 78, 91-102. DOI |
26 | Timothy R, Susan S, Bao-Li Chang, et al (2013). Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer, 2013, 1-12. |
27 | Tel J, Schreibelt G, Sittig SP, et al (2013). Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 121, 459-67. DOI |
28 | Yi XM, Zhou WQ (2010). Epigenetics of prostate cancer. National J Androl, 16, 635-41. |
29 | Yiin JJ, Hu B, Schornack PA, Sengar RS, et al (2010). ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther, 9, 929-41. DOI |
30 | Yang DH, Kim MH, Hong CY, et al (2010). Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol, 89, 795-801. DOI |